-
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
20 Jul 2023 22:03 GMT
… raxibacumab, a monoclonal antibody therapeutic. The FDA approval of CYFENDUS™ vaccine … the vaccine and antibacterial drugs approved … the vaccine. Allergic reactions: Appropriate medical treatment and … services for pharmaceutical and biotechnology customers. To …
-
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
06 Mar 2024 21:31 GMT
… and Drug Administration (“FDA”) approval of CYFENDUS® (Anthrax Vaccine Adsorbed, … zykl) product, a treatment for Ebola
Awarded a … BioThrax®, Anthrasil® and Raxibacumab
Smallpox MCM — comprises … to development of medical countermeasures; the availability …
-
Antibiotic Drug Resistance
25 Sep 2019 05:30 GMT
… .7 Glycopeptides Under Clinical Trials 88 4.8 Glycopeptide … of Key and Secondary Drug Resistance Mutations on Structure … References 468 19 Nontraditional Medicines for Treatment of Antibiotic Resistance 477 … 478 19.2.1 Raxibacumab Versus Bacillus anthracis 478 …
-
Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
04 Oct 2017 14:20 GMT
… S. Food and Drug Administration (FDA) for the treatment and prophylaxis of … acquisition of raxibacumab expands Emergents portfolio of approved medical countermeasures that … Orphan Drug designation in the U.S. Raxibacumab is indicated for the treatment …
-
Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
03 Oct 2017 11:00 GMT
… S. Food and Drug Administration (FDA) for the treatment and prophylaxis of … acquisition of raxibacumab expands Emergent’s portfolio of approved medical countermeasures that … Orphan Drug designation in the U.S. Raxibacumab is indicated for the treatment …
-
Emergent BioSolutions: More Than An Emerging Biotech
16 Nov 2017 01:59 GMT
… , both about 10% below the biotechnology and drug industry average. Product revenues … :GSK) $75 million for raxibacumab, an FDA-approved treatment of inhalation anthrax. The … next-gen anthrax vaccine NuThrax which starts phase III trials next year …
-
Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
19 Jul 2017 20:15 GMT
… portfolio of approved medical countermeasures addressing … and Drug Administration (FDA) for the treatment and … our franchise of vaccines and therapeutics … raxibacumab
Raxibacumab is the first monoclonal antibody approved by the FDA for the treatment …
-
Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
20 Jul 2017 21:44 GMT
… buy French pharmaceutical giant Sanofi's smallpox vaccine business … Raxibacumab, a monoclonal antibody approved by the Food and Drug … Administration for the treatment and prophylaxis … .
Eric Schmidt, a biotechnology analyst for Cowen and …
-
Emergent BioSolutions to buy GSK’s anthrax treatment raxibacumab
20 Jul 2017 04:57 GMT
… the US Food and Drug Administration (FDA) for the treatment and prophylaxis of … deal concludes, Emergent will acquire raxibacumab, including corresponding product rights, … associated manufacturing facilities.
These medicines are currently manufactured at GSK …
-
to acquire anthrax treatment, move manufacturing to Baltimore
20 Jul 2017 00:19 GMT
… and milestone payments to acquire Raxibacumab, a drug used to treat inhaled … plant near Johns Hopkins Bayview Medical Center.
As one of three … next-generation vaccine for adsorbed anthrax, which is currently in trials.
___ …